Robert Kleiman expands role at ERT

Adds chief medical officer to current role as vp of global cardiology

ERT, a US provider of clinical services and medical devices, has appointed Robert Kleiman as chief medical officer. He will also continue in his current role as vice president of Global Cardiology.

Prior to joining ERT in April 2004, Dr Kleiman had worked for ERT as an independent contractor through his cardiology and cardiac electrophysiology practice since 1994. ERT’s cardiology group has more than tripled in size since 2004.

In addition to his current duties, Dr Kleiman will take an increasing consulting and sales role.

Commenting on his appointment, Dr Kleiman said: ‘I have enjoyed my long association with ERT and very much look forward to working with our customers and staff in my new role of working more closely with sponsors to ensure the efficacy and safety of new drugs.’

You may also like

Regulatory

ERT introduces solution to measure Lung Clearance Index

Solution provides greater data granularity to measure disease progression in respiratory trials where standard spirometry is insufficient
Regulatory

ERT recognised for improving and accelerating clinical research

Company named finalist for PACT Technology Company of the Year Award
Regulatory

Exco InTouch launches Gather and redefines the use of mobile technology in clinical trials

New product suite supports patients, sites and sponsors throughout the clinical journey
Regulatory

Scottish Equity Partners takes minority stake in Exco InTouch

Will provide a initial investment of £3m to accelerate mobile patient communication solutions
Regulatory

Almac and Exco InTouch form alliance

To deliver patient compliance as well as ePRO services using multiple technologies
Regulatory

Amcor’s Winterbourne site achieves ISO 13485 certification, strengthening its position and capabilities in healthcare

ISO 13485:2016 is an internationally recognised quality management standard specifically for medical devices.
Regulatory

Roche wins CE mark for first blood-based immunoassay to identify ApoE4 Alzheimer's risk variant

Roche's Elecsys ApoE4 test has received CE mark approval as the first in-vitro diagnostic immunoassay to detect the ApoE4 genetic variant from a simple blood sample, potentially eliminating the need for confirmatory DNA testing in Alzheimer's patients who do not carry the variant
Subscribe now